Progress with NHS England pilots of alternative funding approaches

Market Access
NHS sign on tiles

Leela Barham used a Freedom of Information (FOI) request to find out more about the piloting of alternative funding approaches to drive adoption of innovative medicines, a commitment under the UK-US pharma trade deal.

With details still being finalised as of 6th November, there’s more to do before the pilot can go live from April 2027 as planned.

Pilot of new funding approaches

As part of the UK-US pharma trade deal, the two sides agreed to a series of fast-track pilots to “get innovative medicines to NHS patients faster, and support investment in the UK,” according to a government press release from 2nd July 2026. One of the pilots is “dedicated regional funding to improve patient access to priority medicines, supporting local systems to provide faster and wider uptake of transformative innovations.”

NHS England’s David Glover, assistant director in medicines value & access at NHSE, provided an update on the regional funding pilot in a guest article on the ABPI website on 9th October. NHS England is leading this pilot.

The funding challenges discussed in the blog include financial pressures and suggest that the pilot would “test whether reducing or removing this affordability barrier can contribute to faster, fairer medicines uptake among for those people who are eligible.”

Further development work

A 6th November FOI response from NHS England has revealed that the alternative funding approaches due to be tested aren’t yet finalised. NHS England wrote, “The details of the alternative funding flows is currently still under development and continues as part of the pilot design work.”

The NHS England blog suggests a go-live from April 2027, so there’s still time to figure out the details. However, it might be useful for the NHS Regions who will be receiving a six- to eight-week call for participation slated to start “this Autumn” and with planned selection “before the end of 2026” to know just what they could be signing up for.

The FOI response revealed that NHS England has yet to determine selection criteria for which NHS Regions will take part. The same applies for choice of Integrated Care Boards.

No new money

No new money will be made available for the alternative funding approaches. “All funding for the pilots will be from the existing funding allocated by Parliament as part of the most recent Spending Review. Development of the funding flows continues as part of the pilot design work”, said the NHS England FOI response, so anyone hoping for a genuine funding boost will be left disappointed.

Those who have already raised concerns about funding implications of the UK-US pharma trade deal will likely point out how this means something else that the NHS could have funded must be given up.

Focus on chronic obstructive pulmonary disease (COPD), chronic kidney disease, and heart failure treatments

The NHS England blog had already revealed the therapeutic focus of the pilot - COPD, chronic kidney disease, and heart failure - but no specific medicines were named. NHS England declined to provide them in response to the FOI request, citing an exemption from publishing “where disclosure would or would be likely to prejudice the commercial interests of any person, including the public authority holding the information.”

The FOI response further noted: “Disclosure of the list of commercial products at this stage would prejudice the commercial interests of NHS England and the respective companies. NHS England is of the opinion that disclosure of this information would provide competitors and other parties with information which would not ordinarily be available to them and undermine the commercial ability of the product suppliers. NHS England's commercial interests would also be undermined in future procurements and contract negotiations.”

Will NHS England be marking their own homework?

The NHS England blog said that the pilot is “a learning opportunity.” NHS England will be monitoring NHS Regions that take part and collect data on the use of innovative medicines and “associated impacts.” These impacts weren’t defined.

The FOI response revealed that, “Responsibility for evaluation currently sits within NHS England.” Could that mean that NHS England will be marking their own homework?

The NHS England blog suggests that increased statistics on uptake won’t be the only measure of success: “quality of the evidence generation and the insights it provides for future policy development: will be considered as part of success too.” Hard to know just what that means. The FOI response adds to the NHS England blog by referring to “adoption, unwarranted variation, and patient outcomes” as being in scope, and further that “success criteria is in development and subject to agreement.” No further detail was given.

The pilot is due to run for two years and is due to end in 2029. Time will tell what will be piloted and whether it makes any difference.